# LifeBond

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lifebond

- Industry: Medical Devices & Equipment
- Headquarters: Israel
- Website: www.life-bond.com
- Total disclosed funding: $57M
- Latest round: Series D (Aug 5, 2015)
- Investors on record: 9

## About

LifeBond Ltd. specializes in innovative medical solutions, particularly focused on adhesive technologies that enhance wound healing and surgical procedures, improving patient outcomes across healthcare settings.Founded in 2007, LifeBond Ltd. operates out of Israel, concentrating on developing advanced adhesive solutions for medical applications. In January 2020, the company was acquired by C. R. Bard, Inc. LifeBond Ltd. has successfully completed six deals, with the latest round being a Series D funding of USD 14.50 mn, raised on 15 January 2020, with participation from leading investors including Adams Street Partners and Pitango Venture Capital. The founder's history includes previous ventures in medical technology, although specific details are not provided.LifeBond Ltd. specializes in a range of innovative adhesive products tailored for the medical sector. Its core offerings include advanced surgical adhesives that optimize wound closure and enhance recovery. These products are designed to meet the specific needs of healthcare providers, ensuring safety and efficacy during surgical procedures. The company serves a diverse clientele, including hospitals and medical facilities primarily in North America and Europe, aiming to foster healthier patient outcomes through its specialized solutions.LifeBond Ltd. generates revenue through direct sales of its adhesive products and partnerships with medical distributors. Its financial model encompasses sales agreements with healthcare providers, ensuring a steady stream of income from its core products. Specific pricing structures are established based on product type and volume, which supports varying customer needs and contributes to the firm's market presence.LifeBond Ltd. is focused on expanding its product line with new adhesive solutions scheduled for release in late 2023, aimed at specific surgical applications. The company plans to enter new international markets, specifically targeting regions in Asia and Europe by 2024. Recent funding from the Series D round will support these initiatives, enhancing research and development capabilities as well as expanding market reach following its acquisition by C. R. Bard, Inc.

## Funding rounds

- Series D, Aug 5, 2015, $15M — Adams Street Partners, Pitango, Giza Venture Capital, GlenRock Israel, Sino Biopharmaceutical Limited, Aurum Ventures, BizTEC
- Series D, Sep 30, 2014, $13M — Pitango, Giza Venture Capital, GlenRock Israel, Aurum Ventures
- Series C, Aug 8, 2011, $20M — Pitango, Giza Venture Capital, Johnson & Johnson Innovation, GlenRock Israel, Aurum Ventures, The Zitelman Group
- Series B, Jun 2, 2009, $8M — Pitango, GlenRock Israel, The Zitelman Group
- Series A, Aug 16, 2007, $1.5M — GlenRock Israel, The Zitelman Group

## Investors

- GlenRock Israel (https://capitalatlas.ai/funds/glenrock-israel) — Series A, Series B, Series C, Series D
- The Zitelman Group — Series A, Series B, Series C
- Pitango (https://capitalatlas.ai/funds/pitango) — Series B, Series C, Series D
- Giza Venture Capital (https://capitalatlas.ai/funds/giza-venture-capital) — Series C, Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C
- Aurum Ventures (https://capitalatlas.ai/funds/aurum-ventures) — Series C, Series D
- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series D
- Sino Biopharmaceutical Limited — Series D
- BizTEC — Series D